C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Clinical Trial Collaboration with Pfizer to Combine Cemsidomide and Elranatamab for Multiple Myeloma Treatment
C4 Therapeutics Inc. has announced a clinical trial collaboration and supply agreement with Pfizer Inc. to evaluate a new treatment combination for relapsed or refractory multiple myeloma. Under the agreement, Pfizer will supply its BCMAxCD3 bispecific antibody, elranatamab (ELREXFIO®), for use in an upcoming Phase 1b clinical trial sponsored by C4 Therapeutics. The trial will assess the safety and tolerability of combining cemsidomide, an IKZF1/3 degrader, and dexamethasone with elranatamab as a second-line or later therapy. The collaboration aims to identify an optimal dose for the combination and explore its potential to improve patient outcomes in multiple myeloma. The trial is expected to begin in the second quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538001-en) on October 01, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。